CRC_G029527

IMPOWER010 A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti−PD-L1 Antibody) Compared with Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in PD-L1−Selected Patients with Completely Resected Stage IB−IIIA Non−Small Cell Lung Cancer

The primary efficacy objective of the study is to evaluate the efficacy of 16 cycles of Atezolizumab (MPDL3280A) treatment compared with best supportive care as measured by disease-free survival (DFS) as assessed by the investigator.

Key Inclusion Criteria:

• ECOG 0 – 1

• Stage IB-IIIA NSCLC

• Complete resection of NSCLC

• Tumor PD-L1 expression of TC3 or IC3, as determined by an IHC assay performed by a central laboratory
Phase III
NCT02486718
Cancer
Lung
Kimberly Costas, MD
Roche Holding AG (Hoffman-LaRoche)
Mickella Knapp
  • Providence Regional Cancer Partnership - Everett